Assembly Biosciences (NASDAQ:ASMB) Upgraded at BidaskClub

BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a strong sell rating to a sell rating in a research report released on Thursday morning, BidAskClub reports.

ASMB has been the subject of a number of other research reports. Chardan Capital restated a neutral rating on shares of Assembly Biosciences in a report on Thursday, September 19th. ValuEngine upgraded Assembly Biosciences from a hold rating to a buy rating in a report on Thursday, August 8th. William Blair restated a buy rating on shares of Assembly Biosciences in a report on Wednesday, October 2nd. Zacks Investment Research upgraded Assembly Biosciences from a hold rating to a buy rating and set a $13.00 price objective for the company in a report on Friday, September 27th. Finally, Mizuho initiated coverage on Assembly Biosciences in a report on Tuesday. They set a buy rating and a $20.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Assembly Biosciences has a consensus rating of Buy and an average price target of $27.00.

Shares of NASDAQ:ASMB traded down $0.46 during trading on Thursday, reaching $15.05. 1,541,020 shares of the stock were exchanged, compared to its average volume of 337,299. Assembly Biosciences has a 12 month low of $8.13 and a 12 month high of $27.60. The firm has a market cap of $239.12 million, a PE ratio of -3.78 and a beta of 1.46. The stock has a 50-day moving average price of $11.10 and a 200-day moving average price of $13.89. The company has a current ratio of 9.20, a quick ratio of 9.20 and a debt-to-equity ratio of 0.06.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.41. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. The company had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million. On average, sell-side analysts expect that Assembly Biosciences will post -3.64 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of the stock. Voloridge Investment Management LLC bought a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $226,000. Nuveen Asset Management LLC bought a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $3,681,000. Citadel Advisors LLC boosted its stake in shares of Assembly Biosciences by 90.0% in the second quarter. Citadel Advisors LLC now owns 450,315 shares of the biopharmaceutical company’s stock valued at $6,075,000 after buying an additional 213,363 shares during the period. D. E. Shaw & Co. Inc. bought a new stake in shares of Assembly Biosciences in the second quarter valued at approximately $716,000. Finally, Morgan Stanley boosted its stake in shares of Assembly Biosciences by 75.0% in the second quarter. Morgan Stanley now owns 210,238 shares of the biopharmaceutical company’s stock valued at $2,835,000 after buying an additional 90,080 shares during the period. Institutional investors and hedge funds own 82.00% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Further Reading: What is the Current Ratio?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.